Taevas
PeruPharmaceuticals
Product Registration
Product Registration for Pharmaceuticals in Peru
Taevas Global guides pharmaceuticals manufacturers through Peru's DIGEMID registration process, turning complex regulatory requirements into a clear, executable market entry pathway. From dossier preparation to approval management, we reduce timelines and
Market
Peru
Industry
Pharmaceuticals
Service
Product Registration
Regulator
DIGEMID (Direccion General de Medicamentos, Insumos y Drogas)
Timeline
6-18 months depending on product category
What We Deliver
Six Pillars of Peru Pharmaceuticals Intelligence
Our six interconnected pillars cover every dimension of pharmaceutical product registration in Peru, from regulatory mapping to post-approval lifecycle management.
01
Regulatory Pathway Assessment
We conduct a detailed analysis of DIGEMID registration pathways applicable to your product, including classification under Decree 016-2011-SA and subsequent amendments. This assessment determines whether your product qualifies for standard, abbreviated, or accelerated registration tracks and identifies all mandatory technical requirements upfront.
Product classification under DIGEMID categories
Identification of applicable registration track
Gap analysis against current DIGEMID technical requirements
How It Works
From Brief to Board-Ready Intelligence
Our four-phase engagement model takes you from initial regulatory scoping to a fully submitted and tracked DIGEMID application, with clear milestones and deliverables at every stage.
Step 1 · Day 1-3
Discovery and Regulatory Scoping
We begin with a structured intake session to understand your product portfolio, existing global registrations, and target timeline for Peru market entry. Our regulatory team performs an initial classification review under DIGEMID's product categories and identifies the applicable registration track.
Taevas Approach
During this phase we collect product data sheets, existing CTD dossiers from reference markets, and any prior correspondence with DIGEMID or regional regulators. We produce a Regulatory Scoping Report that outlines the registration pathway, estimated timeline, fee schedule, and a preliminary list of documentation gaps that must be resolved before submission.
Market Snapshot
Peru Pharmaceuticals Market at a Glance
$0B+
Estimated Annual Pharma Market Value (USD)
0%
Projected Annual Market Growth Rate
0+
Licensed Pharmaceutical Companies Operating in Peru
0+
Active Pharmaceutical Registrations with DIGEMID
Growing Generic Segment
Peru's pharmaceutical market is dominated by generic medicines, which account for a significant share of total drug consumption driven by government procurement programs and MINSA essential medicines lists. This creates strong opportunities for generic manufacturers seeking DIGEMID registration, particularly in therapeutic areas such as antibiotics, cardiovascular agents, and diabetes management.
DIGEMID Modernization Drive
DIGEMID has been actively modernizing its registration processes, including the phased introduction of electronic submission systems and alignment with Pan American Health Organization (PAHO) good regulatory practices. Companies that adapt their dossiers to these evolving digital and technical standards gain a meaningful speed advantage over competitors relying on legacy paper-based processes.
Public Sector Procurement Opportunity
A substantial portion of pharmaceutical sales in Peru flows through public sector procurement channels, including CENARES (Centro Nacional de Abastecimiento de Recursos Estrategicos en Salud) and regional health networks. Holding a valid DIGEMID Registro Sanitario is a mandatory prerequisite for participation in any public tender, making timely registration directly linked to revenue opportunity.
Regulatory Convergence with Andean Community
Peru is a member of the Andean Community (CAN), and DIGEMID participates in regional regulatory harmonization initiatives that may allow recognition of registrations granted by equivalent member-state authorities under certain conditions. Understanding these convergence pathways can significantly reduce the documentation burden and timelines for companies already registered in Colombia, Ecuador, or Bolivia.
What's Included
Everything in Your Report
Every Taevas Global Product Registration engagement for Peru Pharmaceuticals delivers eight structured outputs that give your team complete regulatory clarity and commercial confidence.
Regulatory Pathway Report
A detailed written assessment of the applicable DIGEMID registration track for your product, including classification rationale, estimated timeline, fee schedule, and a step-by-step submission roadmap.
DIGEMID-Format Technical Dossier
A fully compiled and reviewed technical dossier structured to DIGEMID requirements, including all administrative, pharmaceutical, non-clinical, and clinical modules with certified Spanish translations.
Documentation Gap Analysis
A module-by-module gap analysis comparing your existing global dossier against current DIGEMID technical requirements, with clear remediation actions and owner assignments.
Regulatory Risk and Mitigation Plan
A structured risk register identifying the most common causes of DIGEMID rejection or delay for your product category, with specific mitigation strategies and contingency timelines.
Peru Market Entry Landscape Brief
A concise briefing on the competitive landscape, key distribution channels, public procurement pathways, and pricing environment relevant to your product category in Peru.
Local Partner Shortlist
A vetted shortlist of qualified local legal representatives and licensed pharmaceutical importers in Peru, with profiles covering DIGEMID standing, therapeutic area experience, and commercial track record.
Submission Tracking Dashboard
Access to a real-time submission tracking dashboard showing application status, DIGEMID query timelines, response deadlines, and milestone completion against the agreed project plan.
Post-Approval Compliance Calendar
A structured post-approval compliance calendar covering the 5-year renewal cycle, variation filing triggers, pharmacovigilance reporting obligations, and labeling update requirements under DIGEMID rules.
Who This Is For
Built for These Situations
Market Entry
Pharmaceuticals Manufacturer Entering Peru for the First Time
Your company has a proven product registered in one or more reference markets and is now targeting Peru as the next growth market in Latin America. You need a reliable regulatory partner who understands DIGEMID's specific requirements and can translate your existing global dossier into a compliant Peruvian submission without starting from scratch.
Outcome
Achieve first DIGEMID Registro Sanitario approval with a complete, compliant dossier and a vetted local representative in place, ready for commercial launch.
Next Steps
After Product Registration, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your Peru Opportunity?
Whether you are entering Peru for the first time or expanding an existing portfolio, Taevas Global's regulatory experts are ready to build a clear, executable DIGEMID registration plan tailored to your product and timeline.
End-to-end DIGEMID dossier preparation and submission management
In-country regulatory expertise with direct DIGEMID engagement experience
Vetted local representative and importer identification
Post-approval lifecycle management including renewals and variations